Medigene AG: Medigene adapts financial forecast 2022

Public disclosure of inside information according to article 17 MAR

Planegg/Martinsried (26.10.2022) - The Executive Management Board of Medigene AG (http://www.medigene.com) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, today resolved to adjust the financial forecast for fiscal year 2022.

Due to the closing of the clinical trial with the product candidate MDG1011 in blood cancer as well as further savings, the forecast for research and development expenses is reduced from previously €11 - 15 m to a range of €9 - 11 m. Consequently, the forecast for earnings before interest, taxes, depreciation and amortization (EBITDA) improves from previously €3 - 5 m to €8 - 9 m.

The Company continues to expect revenues of €23 - 28 m in 2022 and is financed into Q4 2024 on the basis of current planning.

(end)

emitter: Medigene AG

address: Lochhamer Straße 11, 82152 Planegg/Martinsried

country: Germany

contact person: Medigene PR/IR

phone: +49 89 2000 3333 01

e-mail: [email protected]

website: www.medigene.com

ISIN(s): DE000A1X3W00 (share)

stock exchanges: regulated market in Frankfurt; free market in Stuttgart, free market in Munich, free market in Hamburg, free market in Dusseldorf, free market in Hannover; open market in Berlin, Tradegate